60. Aplastic anemia Clinical trials / Disease details
Clinical trials : 235 / Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04854889 (ClinicalTrials.gov) | April 22, 2021 | 14/4/2021 | Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia | Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (LODACA): a Phase 2, Single-arm, Open-label Study | Refractory Aplastic Anemia | Drug: Decitabine | Institute of Hematology & Blood Diseases Hospital | NULL | Recruiting | 12 Years | N/A | All | 45 | Phase 2 | China |